Proteostasis Therapeutics (NASDAQ:PTI) Issues Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Proteostasis Therapeutics (NASDAQ:PTI) released its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.15, Zacks reports.

Shares of NASDAQ PTI opened at $0.90 on Friday. The stock has a market capitalization of $38.86 million, a PE ratio of -0.56 and a beta of -0.59. Proteostasis Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $7.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.19 and a quick ratio of 8.19. The business has a fifty day moving average price of $0.83 and a two-hundred day moving average price of $0.91.

Several research firms recently weighed in on PTI. HC Wainwright reissued a “buy” rating on shares of Proteostasis Therapeutics in a report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Proteostasis Therapeutics in a report on Friday, October 18th. ValuEngine raised Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research cut Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Proteostasis Therapeutics presently has an average rating of “Hold” and an average target price of $6.67.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.

Recommended Story: How the Consumer Price Index (CPI) is calculated?

Earnings History for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.